Welcome to our dedicated page for Meihua International Medical Technologies Co., Ltd. SEC filings (Ticker: MHUA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Meihua International Medical Technologies Co., Ltd. filings document the regulatory record of a Cayman Islands foreign private issuer with operating subsidiaries in China and a disposable medical-device business. Recent Form 6-K reports cover material events, shareholder meeting materials, proxy matters, auditor changes, and capital-structure actions involving its ordinary and Class A ordinary shares.
The company's filings also describe Nasdaq delisting proceedings, the suspension of its Class A ordinary shares from Nasdaq trading, OTC Marketplace trading under the symbol MHUAF, securities purchase agreements, private placement closings, lock-up and leak-out agreements, share consolidation mechanics, governance approvals, and related exhibit documents.
Meihua International Medical Technologies has modified earlier lock-up restrictions on investors in its October 8 and December 5, 2025 private placements. On January 29, 2026, the company entered leak-out agreements that waive the prior 12‑month lock-up on these securities.
Instead of a full resale ban, each purchaser now agrees that, during the leak-out period, sales on any trading day will not exceed 15% of the average daily trading volume over the prior ten trading days, while the ordinary shares trade on specified U.S. exchanges. The leak-out terms apply once the securities are registered for resale or become sellable under Rule 144.
Meihua International Medical Technologies Co., Ltd. reports that investors in its recent private placements have agreed to lock-up restrictions on their shares. The company previously completed an October offering of 40,000,000 ordinary shares (or 400,000 Class A ordinary shares on a post reverse-split and post re-designation basis) for gross proceeds of $15.2 million, and a December offering of up to 120,000 Class A ordinary shares for gross proceeds of $1.32 million. On January 22, 2026, all purchasers from both offerings entered into a lock-up agreement, committing for 12 months after each closing not to sell, pledge, or otherwise dispose of their Meihua securities or seek registration of those securities without the company’s prior written consent.
Meihua International Medical Technologies Co., Ltd. filed an amended report to correct clerical errors in an earlier description of its October 2025 private placement. The company had agreed to sell 40,000,000 ordinary shares at a purchase price of $0.38 per share for gross proceeds of $15.2 million to several non-U.S. purchasers under Regulation S.
According to the updated disclosure, the company issued 24,000,000 ordinary shares to these purchasers on October 17, and on January 20, 2026 it issued the remaining 160,000 class A ordinary shares, par value $0.05 per share, after a 100:1 split and adoption of a dual-class structure, completing the October offering. The company reports 857,914 issued and outstanding class A ordinary shares as of January 20, 2026.
Meihua International Medical Technologies Co., Ltd. reported a change in its independent auditor. Effective December 26, 2025, the board and audit committee dismissed Kreit & Chiu CPA LLP and appointed Li CPA LLC (PCAOB ID: 7093) as the company’s independent registered public accounting firm for the year ended December 31, 2025.
The company states that Kreit & Chiu CPA’s audit reports for 2022, 2023, and 2024 contained no adverse opinions, disclaimers, or qualifications and that there were no disagreements or reportable events under SEC rules during those periods. Meihua also notes it did not previously consult Li CPA on accounting or auditing matters before this engagement. A confirming letter from Kreit & Chiu CPA has been filed as an exhibit.
Meihua International Medical Technologies completed a Regulation S private placement of 120,000 class A ordinary shares at $11 per share, raising gross proceeds of $1,320,000. The company plans to use the net proceeds for working capital and general corporate purposes.
The December investors are non-U.S. persons and made customary investment, business condition, and legal representations under the securities purchase agreement. The filing also notes that in October 2025 Meihua privately placed 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million, and that it currently has 697,914 issued and outstanding class A ordinary shares.
Meihua International Medical Technologies Co., Ltd. (MHUA) reported the results of an extraordinary general meeting held on November 8, 2025. Shareholders holding 38,358,424 of the 55,904,468 ordinary shares outstanding were present in person or by proxy, satisfying the quorum requirement.
Shareholders approved a share consolidation that changes the Company’s authorized share capital from USD50,000 divided into 80,000,000 ordinary shares and 20,000,000 preferred shares, each with a par value of USD0.0005, to USD50,000 divided into 800,000 ordinary shares and 200,000 preferred shares, each with a par value of USD0.05. The voting results on the resolutions showed a very high level of support, with the main proposal receiving 38,304,099 votes in favor, 34,500 against and 27 abstentions.
Meihua International Medical Technologies (MHUA) filed a Form 6-K announcing an extraordinary general meeting of shareholders to be held on November 3, 2025. The filing attaches the Notice of Extraordinary General Meeting and Proxy Statement as Exhibit 99.1 and a Proxy Card as Exhibit 99.2.
As a foreign private issuer, the Notice is not subject to SEC review. Shareholders are encouraged to read the Notice, which provides important details about the Company and the EGM. Documents are available on sec.gov and the Company’s IR site at http://ir.meihuamed.com/, or by written request to the Company’s Yangzhou address.
Meihua International Medical Technologies (MHUA) entered into a securities purchase agreement with certain non‑U.S. persons to sell up to 40,000,000 ordinary shares at $0.38 per share for gross proceeds of $15.2 million. The company states the shares were issued in reliance on Regulation S under the Securities Act.
The closing of the offering is subject to the satisfaction of all closing conditions in the SPA. Meihua currently intends to use the net proceeds for working capital and general corporate purposes. The SPA includes customary representations and covenants, including purchaser status as non‑U.S. persons, no undisclosed material adverse effect, and no legal proceedings that would affect completion.
Meihua International Medical Technologies Co., Ltd. (MHUA) furnished a Current Report on Form 6-K dated September 18, 2025 that attaches unaudited condensed consolidated financial statements covering the six months ended June 30, 2025 and June 30, 2024, plus a Management's Discussion and Analysis of Financial Condition and Results of Operations. The filing includes Inline XBRL exhibits (101.*) and a Cover Page Interactive Data File. The report indicates these exhibits are furnished under the Securities Act and Exchange Act and incorporated by reference into specified Form F-3 and Form F-1 registration statements to the extent not superseded by later filings. The document is signed by the Chief Executive Officer, Leyi Lee.
Meihua International Medical Technologies announced major leadership changes, with its chief executive officer, chief financial officer, and a board member all resigning on August 15, 2025, each citing personal reasons and no disagreements over operations, policies, or practices. On the same day, the board appointed Leyi Lee as the new CEO and director, Shilong Liao as the new CFO, and Anna Colin as an independent director.
Ms. Lee will receive annual compensation of $60,000 for her CEO and board roles, and brings prior leadership experience in sales and commercial strategy at several healthcare and AI companies. Mr. Liao will receive annual compensation of $48,000 as CFO and has held senior finance roles, including at Siemens Healthineers. Ms. Colin will be compensated $1,500 per month as an independent director, has a background in operations at major financial institutions, and will chair the Compensation Committee and serve on the Audit and Nominating and Corporate Governance Committees.